ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
6 announcements with these filters
Suven Life Sciences Limited submitted its Monitoring Agency Report for the quarter ended June 30, 2026. The report confirms the utilization of Rs. 857.64 Crore raised via preferential issue.
Suven Life Sciences has provided a web-link to its Annual Report for FY 2025-2026. This notice informs shareholders whose email addresses are not registered.
Suven Life Sciences Ltd has filed its quarterly shareholding pattern. The document provides details on the current stake distribution between promoters and public shareholders.
Suven Life Sciences announced three poster presentations on Samelisant at the SLEEP-2026 meeting in Baltimore. The disclosure highlights its progressing CNS pipeline and potential partnership opportunities.
Suven Life Sciences reached a 76% enrollment milestone for its Phase 3 Alzheimer's trial. Data readout is expected by April 2027, marking significant clinical progress.
Suven Life Sciences Limited submitted the Regulation 74(5) certificate for the quarter ended March 31, 2026. Issued by KFin Technologies, the certificate confirms compliance regarding the dematerialization and rematerialization of securities. This is a routine quarterly regulatory filing with no material impact on business operations.